insights_auto
Hvorfor har 4142 gått ned? 6,62%?
GÃ¥ mer i dybdenchevron_right
4142:TPE
Adimmune Corp
14,80Â TWD
arrow_downward
−6,62%(−1,05) 1 D
20. nov., 13:30:09 GMT+8 · TWD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for 4142 …
Ã…pne
15,75Â TWD
Høy
15,75Â TWD
Lav
14,80Â TWD
Markedsverdi
6,36Â mrd.
Snittvolum
1,13Â mill.
Volum
1,63Â mill.
P/E-forhold
85,76
52 u høy
21,50Â TWD
52Â u lav
14,80Â TWD
EPS
0,17Â TWD
Utestående aksjer
235,29Â mill.
Antall ansatte
564
Ã…pne
15,75Â TWD
Høy
15,75Â TWD
Lav
14,80Â TWD
Markedsverdi
6,36Â mrd.
Snittvolum
1,13Â mill.
Volum
1,63Â mill.
P/E-forhold
85,76
52 u høy
21,50Â TWD
52Â u lav
14,80Â TWD
EPS
0,17Â TWD
Utestående aksjer
235,29Â mill.
Antall ansatte
564
Nyhetssaker
Fra nettkilder og nyhetspartnere
Adam Feldman | Substack
·
for 17 timer siden
Inside the Federal Litigation of Five S&P 500 Giants
Trefis
·
for 4 timer siden
S&P 500 Movers | Winners: PANW, OKTA, P | Losers: WSM, TWLO, AMD
The Harvard Law School Forum on Corporate Governance
·
for 23 timer siden
Board Practices and Composition in the Russell 3000 and S&P 500
Yahoo Finance
·
for 2 timer siden
Nvidia Has Lost More Than the Market Value of 495 S&P 500 Companies in 6 Weeks -- and Its Downtrend May Be Just Beginning
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Om Adimmune Corp
Administrerende direktør-
Ansatte564
Grunnlagt1965
Hovedkontor-
SektorHealth Care
Bransje-
Nettstedadimmune.com.tw